Some symptomatic benefit was seen in patients with milder disease
The results of a study presented at the Annual European Congress of Rheumatology (EULAR 2018) show that a one-yearly infusion of zoledronic acid (ZA) did not significantly reduce knee pain or bone marrow lesion (BML) size overall in knee osteoarthritis patients over two years. However, it may have symptomatic benefit in milder disease.1
Use of nonsteroidal anti-inflammatory drugs (NSAIDs) was associated with an 18% increased risk of atrial fibrillation—an irregular, often rapid heart rate—in a study of middle-aged adults in Taiwan. The findings are published in the British Journal of Clinical Pharmacology.
Worldwide, overuse of inappropriate tests and treatments such as imaging, opioids and surgery means patients are not receiving the right care, and resources are wasted
Low back pain is the leading cause of disability worldwide, affecting an estimated 540 million people at any one time. Yet, a new Series of papers in The Lancet highlights the extent to which the condition is mistreated, often against best practice treatment guidelines.
A new Arthritis Care & Research study found that moderate-to-vigorous physical activity levels are similarly low in older adults with symptomatic knee osteoarthritis and those from the general population without osteoarthritis or knee pain.
Prior studies have suggested that non-steroidal anti-inflammatory drugs (NSAIDs) may be linked with higher cardiovascular risks, but few have assessed potential different cardiovascular risk between NSAID classes or across individual NSAIDs.
When investigators compared initial bone parameters with changes in those parameters over time in postmenopausal women, they found that initial measurements were significantly associated with women’s risk of fracture.